BioIVT

BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes

Westbury, NY - August 8, 2022 - BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypexís extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is introducing a new internal cloud-based Quality Management System (QMS), Master Control. This new standardized, ISO compliant QMS will help BioIVT manage documentation, auditing, supplier and customer accounts, and risk across all locations. It will consolidate and...

BioIVT Appoints Alan Findlater as Chief Commercial Officer

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVTís commercial activities, including global sales, marketing and customer service.
PO Box 770, Hicksville, NY, 11802-0770

+1 516 483 1196